| Income Statement | 2026-06-30 | |||
|---|---|---|---|---|
| Net sales | 34,463 | |||
| Net sales to a related party | 23,459 | |||
| Cost of sales | 25,297 | |||
| Gross profit | 32,625 | |||
| Payroll, benefits and related taxes | 184,743 | |||
| Professional fees | 171,850 | |||
| Consulting expenses | 81,246 | |||
| Other selling, general and administrative costs | 30,250 | |||
| Total operating expenses | 468,089 | |||
| Loss from operations | -435,464 | |||
| Other income | 2,305 | |||
| Interest expense | 103,922 | |||
| Interest expense to related parties | 6,248 | |||
| Change in fair value of convertible notes and derivatives | -3,405,443 | |||
| Total other expenses, net | -3,513,308 | |||
| Loss before income taxes | -3,948,772 | |||
| Net (loss) income | -3,948,772 | |||
| Basic EPS | 0 | |||
| Diluted EPS | 0 | |||
| Basic Average Shares | 8,066,882,434 | |||
| Diluted Average Shares | 8,066,882,434 | |||
NUTRA PHARMA CORP (NPHC)
NUTRA PHARMA CORP (NPHC)